Is it enough for COVID-19 screening test? Limitation of swab test and general characteristics of mild symptom patients.
Sungwoo ChoiHyo Jeong ChoiHo Jung KimPublished in: Science progress (2021)
The most common method for SARS-CoV-2 testing is throat or nasal swabbing by real-time reverse transcription polymerase chain reaction (RT-PCR) assay. In South Korea, drive-through swab test is used for screening system and community treatment centers (CTCs), which admit and treat confirmed COVID-19 patients with mild symptoms, are being used. This retrospective study was conducted on patients admitted to a CTC on March 6, 2020. A total of 313 patients were admitted. The nasal and throat swabs were collected from the upper respiratory tract, and a sputum test was performed to obtain lower respiratory samples. The positive rate of the first set of test, sputum test was higher than that of the swab test (p = 0.011). In the second set of test, 1 week after the first ones, the rate of positive swab tests was relatively high (p = 0.026). In the first set of test, 66 of 152 (43.4%) patients showed 24-h consecutive negative swab test results, when the sputum test results were considered together, that number fell to 29 patients (19.1%) (p < 0.001). Also, in the second set of test, 63 of 164 (38.4%) patients met the discharge criteria only when the swab test was considered; that number fell to 30 (18.3%) when the sputum test results were also considered (p < 0.001). Using the swab test alone is insufficient for screening test and discharge decision. Patients who may have positive result in the sputum test can be missed.
Keyphrases
- sars cov
- end stage renal disease
- newly diagnosed
- ejection fraction
- mycobacterium tuberculosis
- healthcare
- peritoneal dialysis
- coronavirus disease
- prognostic factors
- mental health
- clinical trial
- respiratory tract
- pulmonary tuberculosis
- tyrosine kinase
- single cell
- circulating tumor cells
- study protocol
- cell free
- circulating tumor